Early Warning System

EIB-20190318 AM-PHARMA (IDFF)



Early Warning System AM-PHARMA (IDFF)

Quick Facts

Countries	Netherlands
Financial Institutions	European Investment Bank (EIB)
Status	Approved
Bank Risk Rating	U
Voting Date	2019-12-19
Borrower	AM-PHARMA HOLDING B.V.
Sectors	Industry and Trade
Investment Type(s)	Loan
Investment Amount (USD)	\$ 26.69 million
Loan Amount (USD)	\$ 26.69 million
Project Cost (USD)	\$ 54.50 million

Project Description

According to EIB website, the transaction will support R&D investments required to bring a product to the market addressing a high unmet medical need, in a growing patient population, preserving and cultivating highly skilled employment opportunities.

Investment Description

• European Investment Bank (EIB)



Early Warning System AM-PHARMA (IDFF)

Private Actor 1	Private Actor 1 Role	Private Actor 1 Sector	Relation	Private Actor 2	Private Actor 2 Role	Private Actor 2 Sector
-	-	-	-	AM-Pharma BV	Client	-

Contact Information

No contact information provided at the time of disclosure.

ACCOUNTABILITY MECHANISM OF EIB

The EIB Complaints Mechanism is designed to facilitate and handle complaints against the EIB by individuals, organizations or corporations affected by EIB activities. When exercising the right to lodge a complaint against the EIB, any member of the public has access to a two-tier procedure, one internal - the Complaints Mechanism Office - and one external - the European Ombudsman. A complaint can be lodged via a written communication addressed to the Secretary General of the EIB, via email to the dedicated email address complaints@eib.org, by completing the online complaint form available at the following address: http://www.eib.org/complaints/form, via fax or delivered directly to the EIB Complaints Mechanism Division, any EIB local representation office or any EIB staff. For further details, check:

http://www.eib.org/attachments/strategies/complaints mechanism policy en.pdf

When dissatisfied with a complaint to the EIB Complaints Mechanism, citizens can then turn towards the European Ombudsman. A memorandum of Understanding has been signed between the EIB and the European Ombudsman establishes that citizens (even outside of the EU if the Ombudsman finds their complaint justified) can turn towards the Ombudsman on issues related to 'maladministration' by the EIB. Note that before going to the Ombudsman, an attempt must be made to resolve the case by contacting the EIB. In addition, the complaint must be made within two years of the date when the facts on which your complaint is based became known to you. You can write to the Ombudsman in any of the languages of the European Union. Additional details, including filing requirements and complaint forms, are available at: http://www.ombudsman.europa.eu/atyourservice/interactiveguide.faces

Bank Documents

• Environmental and Social Data Sheet (ESDS) - AM-PHARMA (IDFF)